
SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...

BioLamina AB bags €19m funding for expansion
The tenth investement from Lauxera Capital Partners through its Lauxera Growth I fund will be usesd by the Swedish company to expand the development...

Pierre Fabre Laboratories collaborate with Vernalis
The French biotech company combines its experience in innovation, development, manufacturing, and commercialisation in oncology with the expertise of...

Sanofi licences vaccine against bacterial sepsis
Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...

AMR: Partnership set to improve in vivo antibiotics testing
The development of novel antibiotics is crucial in the fight against antimicrobial resistance (AMR) but has been neglected for decades due to a lack...

Study links TCM with effects on protein networks
The framework, validated with hospital patient data, is among the first to provide a scientific foundation to evaluate the therapeutic efficacy of...

Recordbreaking BIO-Europe in Munich, but: back to 2019
Record figures and a much better mood in Europe than one is currently hearing from the USA. Financing is difficult at the moment and the US...